Limits...
Potential Serum Markers for Monitoring the Progression of Hepatitis B Virus-Associated Chronic Hepatic Lesions to Liver Cirrhosis.

Wu C, Liu L, Zhao P, Tang D, Yao D, Zhu L, Wang Z - Gut Liver (2015)

Bottom Line: Using SELDI-TOF MS, serum protein/peptide profiles on the CM10 ProteinChip arrays were obtained from a training group including 26 HBV-associated hepatocellular carcinoma patients with liver cirrhosis (LC), 30 HBV-associated LC patients, 85 patients at different stages of liver fibrosis, and 30 asymptomatic HBV carriers.A SELDI peak of M/Z 5805 with value for predicting LC in HBV-infected patients was found and was identified as a peptide of the C-terminal fraction of the fibrinogen a-chain precursor, isoform 1.The peptide of the C-terminal fraction of the fibrinogen α-chain precursor, isoform 1 with M/Z 5805, may be a serological biomarker for progression to LC in HBV-infected patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Digestive Endoscopy, Division of Southern Building, Chinese PLA General Hospital, Beijing,China.

ABSTRACT

Background/aims: To screen for serum protein/peptide biomarkers of hepatitis B virus (HBV)-associated chronic hepatic lesions in an attempt to profile the progression of HBV-associated chronic hepatic lesions using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) techniques.

Methods: Using SELDI-TOF MS, serum protein/peptide profiles on the CM10 ProteinChip arrays were obtained from a training group including 26 HBV-associated hepatocellular carcinoma patients with liver cirrhosis (LC), 30 HBV-associated LC patients, 85 patients at different stages of liver fibrosis, and 30 asymptomatic HBV carriers. The most valuable SELDI peak for predicting the progression to LC in HBV-infected patients was identified.

Results: A SELDI peak of M/Z 5805 with value for predicting LC in HBV-infected patients was found and was identified as a peptide of the C-terminal fraction of the fibrinogen a-chain precursor, isoform 1.

Conclusions: The peptide of the C-terminal fraction of the fibrinogen α-chain precursor, isoform 1 with M/Z 5805, may be a serological biomarker for progression to LC in HBV-infected patients.

No MeSH data available.


Related in: MedlinePlus

The 5805 peak profiling in the control, liver fibrosis (LF), liver cirrhosis (LC), and hepatocellular carcinoma (HCC) groups showed that the intensity of the 5805 peak was much higher in the LC and HCC groups. The 5805-Da protein is a potential biomarker for differentiating LC from stage IV fibrosis and predicting the progression of hepatitis B virus-related liver diseases.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4562785&req=5

f1-gnl-09-665: The 5805 peak profiling in the control, liver fibrosis (LF), liver cirrhosis (LC), and hepatocellular carcinoma (HCC) groups showed that the intensity of the 5805 peak was much higher in the LC and HCC groups. The 5805-Da protein is a potential biomarker for differentiating LC from stage IV fibrosis and predicting the progression of hepatitis B virus-related liver diseases.

Mentions: Among the 18 proteins, 5805 Da protein (p<0.0001) is the most significant peak. Our data indicated that 5805 Da protein is undetected in control group while expressed upward from control to liver fibrosis (stage I–IV), LC and HCC, with the big hoist in LC and HCC groups (p=0.003) (Table 3, Fig. 1). In this way, 5805 Da protein could be a potential biomarker for identifying LC from fibrosis stage IV and predict the progress of HBV-related liver diseases. The diagnostic sensitivity and specificity reach 73.3% and 85%, respectively when 5805 Da peak is applied as the biomarker for distinguishing LC (Ishak=6) from fibrosis stage IV (Ishak=5). The area under the receiver characteristic curve was 0.77 (Fig. 2). The cutoff value was Intensitym/z=5805 3.6.


Potential Serum Markers for Monitoring the Progression of Hepatitis B Virus-Associated Chronic Hepatic Lesions to Liver Cirrhosis.

Wu C, Liu L, Zhao P, Tang D, Yao D, Zhu L, Wang Z - Gut Liver (2015)

The 5805 peak profiling in the control, liver fibrosis (LF), liver cirrhosis (LC), and hepatocellular carcinoma (HCC) groups showed that the intensity of the 5805 peak was much higher in the LC and HCC groups. The 5805-Da protein is a potential biomarker for differentiating LC from stage IV fibrosis and predicting the progression of hepatitis B virus-related liver diseases.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4562785&req=5

f1-gnl-09-665: The 5805 peak profiling in the control, liver fibrosis (LF), liver cirrhosis (LC), and hepatocellular carcinoma (HCC) groups showed that the intensity of the 5805 peak was much higher in the LC and HCC groups. The 5805-Da protein is a potential biomarker for differentiating LC from stage IV fibrosis and predicting the progression of hepatitis B virus-related liver diseases.
Mentions: Among the 18 proteins, 5805 Da protein (p<0.0001) is the most significant peak. Our data indicated that 5805 Da protein is undetected in control group while expressed upward from control to liver fibrosis (stage I–IV), LC and HCC, with the big hoist in LC and HCC groups (p=0.003) (Table 3, Fig. 1). In this way, 5805 Da protein could be a potential biomarker for identifying LC from fibrosis stage IV and predict the progress of HBV-related liver diseases. The diagnostic sensitivity and specificity reach 73.3% and 85%, respectively when 5805 Da peak is applied as the biomarker for distinguishing LC (Ishak=6) from fibrosis stage IV (Ishak=5). The area under the receiver characteristic curve was 0.77 (Fig. 2). The cutoff value was Intensitym/z=5805 3.6.

Bottom Line: Using SELDI-TOF MS, serum protein/peptide profiles on the CM10 ProteinChip arrays were obtained from a training group including 26 HBV-associated hepatocellular carcinoma patients with liver cirrhosis (LC), 30 HBV-associated LC patients, 85 patients at different stages of liver fibrosis, and 30 asymptomatic HBV carriers.A SELDI peak of M/Z 5805 with value for predicting LC in HBV-infected patients was found and was identified as a peptide of the C-terminal fraction of the fibrinogen a-chain precursor, isoform 1.The peptide of the C-terminal fraction of the fibrinogen α-chain precursor, isoform 1 with M/Z 5805, may be a serological biomarker for progression to LC in HBV-infected patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Digestive Endoscopy, Division of Southern Building, Chinese PLA General Hospital, Beijing,China.

ABSTRACT

Background/aims: To screen for serum protein/peptide biomarkers of hepatitis B virus (HBV)-associated chronic hepatic lesions in an attempt to profile the progression of HBV-associated chronic hepatic lesions using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) techniques.

Methods: Using SELDI-TOF MS, serum protein/peptide profiles on the CM10 ProteinChip arrays were obtained from a training group including 26 HBV-associated hepatocellular carcinoma patients with liver cirrhosis (LC), 30 HBV-associated LC patients, 85 patients at different stages of liver fibrosis, and 30 asymptomatic HBV carriers. The most valuable SELDI peak for predicting the progression to LC in HBV-infected patients was identified.

Results: A SELDI peak of M/Z 5805 with value for predicting LC in HBV-infected patients was found and was identified as a peptide of the C-terminal fraction of the fibrinogen a-chain precursor, isoform 1.

Conclusions: The peptide of the C-terminal fraction of the fibrinogen α-chain precursor, isoform 1 with M/Z 5805, may be a serological biomarker for progression to LC in HBV-infected patients.

No MeSH data available.


Related in: MedlinePlus